Data are available within the supporting information files.

Introduction {#sec001}
============

Cigarette smoking is a risk factor for various diseases, such as cancers including lung cancer, chronic obstructive pulmonary disease (COPD), hypertension, ischemic heart disease, and cerebrovascular disorders. According to the WHO, more than 6 million people die annually due to cigarette smoking \[[@pone.0163583.ref001]\]. Medical and social economic losses due to cigarette smoking are approximately 1.8 and 2.4 trillion yen (approximately 15 and 20 billion dollars), respectively, in Japan \[[@pone.0163583.ref002]\], and approximately 170 and 156 billion dollars, respectively, in the US \[[@pone.0163583.ref003],[@pone.0163583.ref004]\]. Therefore, the cost-effectiveness of smoking cessation treatment (SCT) for the prevention of secondary diseases is high \[[@pone.0163583.ref005]\], and it is recommended as part of health care cost controls. Pharmacological treatments are used as SCT, of which there are 2 types: 'nicotine replacement therapy using nicotine preparations' and 'the use of the partial agonist of the nicotinic acetylcholine receptor, varenicline (VAR)'. A previous study reported that VAR is less likely to cause nicotine withdrawal symptoms and has a higher success rate than nicotine preparations \[[@pone.0163583.ref006]\]; therefore, it is regarded as an important drug for the promotion of non-smoking policies.

However, VAR has been implicated in the aggravation of mental diseases, such as depression, and suicide, and, as a consequence, the Food and Drug Administration (FDA) issued a warning in 2009 \[[@pone.0163583.ref007]\]. In Japan, the following description was added to the warning column of the package insert: It may aggravate underlying mental diseases. In the retrieval system in Japanese, CzeekV (2015/04/13 access, version 2.1.1), of the FDA voluntary adverse event report database, the Adverse Event Reporting System (FAERS), VAR is ranked in first place in the overall ranking of signals of suicidal ideation and behavior. On the other hand, a meta-analysis of randomized controlled studies showed that VAR was not associated with depression or suicide \[[@pone.0163583.ref008]\]. Therefore, while VAR is unlikely to cause depression and suicide, smoking cessation itself has been suggested to induce depression and suicide \[[@pone.0163583.ref009]\], and cigarette smokers are at a high risk of depression \[[@pone.0163583.ref010]\].

SSRI and SNRI, which cause few adverse reactions, are currently used as first-line drugs to treat depression \[[@pone.0163583.ref011]\]; however, an increase in the risk of suicide by the administration of antidepressants (ADs) was confirmed in a placebo controlled trial, and the FDA issued a warning for all SSRIs in 2003. Moreover, several studies reported AD-induced increases in suicide-related events (SRE) \[[@pone.0163583.ref012]--[@pone.0163583.ref014]\]. On the other hand, after a warning concerning ADs and suicide was issued in the US and Europe, the prescription rate of ADs decreased in the Netherlands with a simultaneous increase in the suicide rate \[[@pone.0163583.ref015]\], whereas an inverse correlation was noted between the number of prescriptions for ADs and suicide mortality \[[@pone.0163583.ref016]\], showing different study results due to differences in the study method.

Smoking cessation is economically important and a policy that needs to be promoted, as described above; however, the development of depression and SRE during SCT represents a major obstacle to smoking cessation.

Thus, we herein attempted to identify ADs with the lowest risk of SRE among the ADs concomitantly used in SCT with VAR from the viewpoint of the safe use of drugs by comparing the risk of SRE between VAR-treated cases with (ADs+/VAR+) and without (ADs-/VAR+) concomitant ADs treatment (Study 1). The risks associated with the administration of VAR were investigated, with consideration of the information provided by the regulatory agency that 'VAR aggravates mental disease'. AD-treated cases were divided into those with (VAR+/ADs+) and without (VAR-/ADs+) concomitantly administered VAR and were then compared in order to examine whether VAR increases the risk of SRE (Study 2). The risk of SRE was standardized by regarding the risk as identical between ADs+/VAR+ in Study 1 and VAR+/ADs+ in Study 2, and the risk was compared between ADs-/VAR+ and VAR-/ADs+ to investigate the risk of SRE in VAR-treated cases without ADs, i.e., the latent risk of the use of VAR.

Methods {#sec002}
=======

Study 1: Concomitant AD-associated risk of SRE in VAR-treated (SCT) cases {#sec003}
-------------------------------------------------------------------------

### Definition of SRE {#sec004}

In the ICH Medical Dictionary for Regulatory Activities/Japanese version (MedDRA/J), the SMQ classification of SRE includes the following terms at the Preferred Term (PT) level: Completed suicide (MedDRA code 10010144), suicidal ideation (10042458), suicide attempt (10042464), suicidal behavior (10065604), self-injurious ideation (10051154), self-injurious behavior (10063495), depression suicidal (10012397), intentional self-injury (10022524), poisoning deliberate (10036000), and intentional overdose (10022523), and these were collectively defined as SRE.

### Data extraction and adjustment {#sec005}

Since FAERS adopts a free-description style to enable reporting with ease, incorrect inputs and overlapping data are included. CzeekV is a unique system that organizes these data and enables searches in Japanese \[[@pone.0163583.ref017]\]. In the present study, all VAR-treated cases were collected from CzeekV (version 2.1.1), cases treated with 2 or more ADs were excluded, and the remaining cases were adopted as an analysis set for the case-control study. The data of this system is replaced FAERS database in Japanese. Therefore, the dataset in this study do not include any of identifying information. In order to remove selection biases as much as possible, after stratifying by gender, cases were matched based on the Propensity Score (PS) using the Statistical Package for Social Science (SPSS, version 22). In the PS estimation, 3 case background factors: age, body weight, and number of concomitantly administered drugs, were regarded as covariates, and the presence or absence of SRE was regarded as the outcome. It was not possible to apply stratification by disease severity because it was not included in case reports in FAERS. Although age was reported in many cases, the number was insufficient to analyze cases stratified by gender. Thus, only stratification by gender, a factor influencing the drug effect, was applied. A multiple logistic regression analysis employing the stepwise method was used in the PS estimation, and the PS distance (caliper value) was defined as '0.25 x the standard deviation of the logit transformation-applied PS estimate'. Using the PS estimate and caliper value, the SRE+ and SRE- (control) groups were matched. The standardized difference (SDD) was calculated in order to evaluate the balance of covariates of the matched data \[[@pone.0163583.ref018]\]. An SDD value of less than 0.1 was regarded as balanced \[[@pone.0163583.ref019]\]. A flow chart of the process used for reporting odds ratio (ROR) calculations is shown in [Fig 1](#pone.0163583.g001){ref-type="fig"}.

![Flowchart for ROR calculations.\
\* Reporting Odds Ratio. \*\* integrated Reporting Odds Ratio.](pone.0163583.g001){#pone.0163583.g001}

### Calculation of the ROR and corresponding 95% confidence interval (ROR95%CI) {#sec006}

In order to investigate the risk of SRE in VAR-treated cases with concomitant ADs (ADs+/VAR+) using matched data, the ROR and ROR95%CI were calculated in each gender with the concomitant use of ADs as a factor and in the presence or absence of SRE as the outcome. In addition, the uniformity of ROR of the matched data between genders was evaluated using the Breslow-Day Test, and when ROR was uniform, the integrated ROR (iROR) and corresponding 95% CI (iROR95%CI) of ADs were calculated using the Mantel-Haenszel Test. We corrected the significance level by employing the Bonferroni method in consideration of the alpha error made by multiple comparisons \[[@pone.0163583.ref020]\].

Study 2: Concomitant VAR (SCT)-associated risk of SRE in AD-treated cases {#sec007}
-------------------------------------------------------------------------

In order to investigate the risk of SRE in AD-treated cases with concomitantly administered VAR (VAR+/ADs+), AD-treated cases were collected, and those using only one AD were extracted. PS was estimated after stratification of this analysis set by gender, as described in Study 1. Cases were divided into those with and without SRE, and the 2 groups were matched. In addition, in order to investigate the influence of concomitantly administered VAR (SCT) on SRE using matched data, ROR and ROR 95% CI were calculated with the concomitant use of VAR as a factor and in the presence or absence of SRE as the outcome. The uniformity of matched data between genders was evaluated using the Breslow-Day Test, and when ROR was uniform, iROR and iROR95%CI of the AD were calculated using the Mantel-Haenszel Test.

Results {#sec008}
=======

Study 1: Concomitant AD-associated risk of SRE in VAR-treated (SCT) cases {#sec009}
-------------------------------------------------------------------------

Changes in the number of VAR-treated cases with the flowchart in [Fig 1](#pone.0163583.g001){ref-type="fig"} are shown in [S1 Table](#pone.0163583.s001){ref-type="supplementary-material"}. The balance of the covariates before and after matching is shown in [S2 Table](#pone.0163583.s002){ref-type="supplementary-material"}. The SDD values of all covariates after matching were less than 0.1, which was close to randomization.

Using matched data, ROR and ROR 95% CI were calculated with the presence or absence of concomitantly administered ADs in VAR-treated cases as a factor and in the presence or absence of SRE as an outcome. The results obtained are summarized in [Table 1](#pone.0163583.t001){ref-type="table"} (see the minimal dataset in [S3 Table](#pone.0163583.s003){ref-type="supplementary-material"}).

10.1371/journal.pone.0163583.t001

###### Influence of concomitantly administered ADs on the risk of SRE in VAR-treated cases.

![](pone.0163583.t001){#pone.0163583.t001g}

  ---------------------- ----------------------- --------------- ---------- ---------- --------- --------------- -----------------------------------------------
  **Male**                                                                                                       
                         **VAR-treated cases**                                                                   
                         **ADs+/VAR+**           **ADs-/VAR+**                                                   
                         **SRE+**                **SRE-**        **SRE+**   **SRE-**   **ROR**   **ROR 95%CI**   **p-value**
  All AD-treated cases   58                      30              601        629        2.02      1.28--3.19      0.002[\*](#t001fn002){ref-type="table-fn"}
  By drug                                                                                                        
  Mirtazapine            7                       1               601        629        7.33      0.90--59.73     0.063
  Citalopram             12                      2               601        629        6.28      1.40--28.18     0.016
  Bupropion              9                       4               601        629        2.35      0.72--7.69      0.157
  Duloxetine             6                       3               601        629        2.09      0.52--8.41      0.299
  Fluoxetine             5                       3               601        629        1.74      0.42--7.33      0.45
  Venlafaxine            5                       3               601        629        1.74      0.42--7.33      0.45
  Sertraline             9                       6               601        629        1.57      0.56--4.44      0.395
  Amitriptyline          2                       2               601        629        1.05      0.15--7.45      0.961
  Paroxetine             3                       3               601        629        1.05      0.21--5.21      0.952
  **Female**                                                                                                     
                         **VAR-treated cases**                                                                   
                         **ADs+/VAR+**           **ADs-/VAR+**                                                   
                         **SRE+**                **SRE-**        **SRE+**   **SRE-**   **ROR**   **ROR 95%CI**   **p-value**
  All AD-treated cases   163                     86              746        823        2.09      1.58--2.76      \< 0.001[\*](#t001fn002){ref-type="table-fn"}
  By drug                                                                                                        
  Mirtazapine            6                       1               746        823        6.62      0.80--55.11     0.08
  Sertraline             19                      6               746        823        3.49      1.39--8.79      0.008
  Duloxetine             21                      7               746        823        3.31      1.40--7.83      0.006
  Bupropion              15                      6               746        823        2.76      1.06--7.15      0.037
  Fluoxetine             27                      14              746        823        2.13      1.11--4.09      0.023
  Venlafaxine            25                      13              746        823        2.12      1.08--4.18      0.03
  Trazodone              6                       4               746        823        1.65      0.47--5.89      0.439
  Citalopram             12                      13              746        823        1.02      0.46--2.25      0.961
  Amitriptyline          5                       11              746        823        0.5       0.17--1.45      0.201
  Paroxetine             21                      0               746        823        Inf       5.71---Inf      not calculated
  Nortriptyline          3                       0               746        823        Inf       0.45---Inf      not calculated
  Amoxapine              1                       0               746        823        Inf       0.03 -Inf       not calculated
  Clomipramine           1                       0               746        823        Inf       0.03 -Inf       not calculated
  Trimipramine           1                       0               746        823        Inf       0.03 -Inf       not calculated
  Lofepramine            1                       0               746        823        Inf       0.03 -Inf       not calculated
  Imipramine             0                       1               746        823        0         0.00---Inf      not calculated
  ---------------------- ----------------------- --------------- ---------- ---------- --------- --------------- -----------------------------------------------

Inf, infinite.

\* significantly different after Bonferroni's correction for multiple comparisons.

In male cases ([Table 1](#pone.0163583.t001){ref-type="table"}-male), concomitantly administered ADs significantly increased the risk of SRE (ROR 2.02, ROR95%CI 1.28--3.19). Nine types of ADs were extracted, as shown in [Table 1](#pone.0163583.t001){ref-type="table"}-male. None of the antidepressants tested significantly increased the risk of SRE after the correction of the significance level by the Bonferroni method.

Concomitantly administered ADs also significantly increased the risk of SRE in female cases (ROR 2.09, ROR95%CI 1.58--2.76) ([Table 1](#pone.0163583.t001){ref-type="table"}-female). Sixteen types of ADs were extracted, as shown in [Table 1](#pone.0163583.t001){ref-type="table"}-female. None of the antidepressants tested significantly increased the risk of SRE after the correction of the significance level by the Bonferroni method.

The results of the ROR uniformity test (Breslow-Day Test) and iROR calculation (Mantel-Haenszel Test) are shown in [Table 2](#pone.0163583.t002){ref-type="table"}. As shown by values marked with ^a^ in [Table 2](#pone.0163583.t002){ref-type="table"}, the ROR of citalopram was not uniform between the genders. In the other ADs, ROR was uniform and it was possible to calculate iROR. As shown in [Table 2](#pone.0163583.t002){ref-type="table"}, concomitantly administered ADs significantly increased the risk of SRE (iROR 2.07, iROR95%CI 1.63--2.63), while only duloxetine (ROR 2.94, ROR95%CI 1.41--6.10) significantly increased the risk of SRE. iROR was less than 1.00 in amitriptyline-treated cases only, but was not significant. Since there was no reported male case of concomitantly administered nortriptyline, amoxapine, clomipramine, trimipramine, lofepramine, or imipramine, it was impossible to investigate uniformity.

10.1371/journal.pone.0163583.t002

###### Uniformity test of ROR (Breslow-Day Test) and calculation of integrated ROR (Mantel-Haenszel Test) in VAR-treated cases.

![](pone.0163583.t002){#pone.0163583.t002g}

                         Breslow-Day Test   Mantel-Haenszel Test                                                                                                                                 
  ---------------------- ------------------ ---------------------- --------------------------------------------- --------------------------------------- --------------------------------------- -----------------------------------------------
  All AD-treated cases   0.015              1.00                   0.904                                         2.07                                    1.63--2.63                              \< 0.001[\*](#t002fn004){ref-type="table-fn"}
  By drug                                                                                                                                                                                        
  Mirtazapine            0.004              1.00                   0.947                                         6.98                                    1.57--30.99                             0.007
  Duloxetine             0.304              1.00                   0.581                                         2.94                                    1.41--6.10                              0.004[\*](#t002fn004){ref-type="table-fn"}
  Bupropion              0.042              1.00                   0.838                                         2.59                                    1.24--5.45                              0.015
  Sertraline             1.296              1.00                   0.255                                         2.52                                    1.26--5.02                              0.009
  Fluoxetine             0.061              1.00                   0.805                                         2.06                                    1.14--3.73                              0.022
  Venlafaxine            0.059              1.00                   0.809                                         2.05                                    1.11--3.78                              0.028
  Trazodone              0.194              1.00                   0.660                                         1.39                                    0.51--3.76                              0.518
  Amitriptyline          0.427              1.00                   0.513                                         0.59                                    0.23--1.50                              0.360
  Citalopram             5.010              1.00                   0.025[^a^](#t002fn002){ref-type="table-fn"}   [\#](#t002fn003){ref-type="table-fn"}   [\#](#t002fn003){ref-type="table-fn"}   not calculated

df, degree of freedom.

^a^ non-uniformity.

^\#^ Value could not be calculated due to the non-uniformity of ROR.

\* significantly different after Bonferroni's correction for multiple comparisons.

Study 2: Concomitant VAR (SCT)-associated risk of SRE in AD-treated cases {#sec010}
-------------------------------------------------------------------------

Changes in the number of AD-treated cases with the flowchart in [Fig 1](#pone.0163583.g001){ref-type="fig"} are shown in [S1 Table](#pone.0163583.s001){ref-type="supplementary-material"}. The 8 types of ADs, the ROR of which were recognized as uniform in [Table 2](#pone.0163583.t002){ref-type="table"}, were analyzed in Study 2. Cases treated with these 8 drugs were stratified by gender and 1-to-1 matched. The results obtained are shown in [S2 Table](#pone.0163583.s002){ref-type="supplementary-material"}. Using matched data, ROR and ROR 95% CI were calculated in the presence or absence of concomitantly administered VAR in AD-treated cases as a factor and in the presence or absence of SRE as an outcome. The results obtained are summarized in [Table 3](#pone.0163583.t003){ref-type="table"}.

10.1371/journal.pone.0163583.t003

###### Influence of concomitantly administered VAR on the risk of SRE in AD-treated cases.

![](pone.0163583.t003){#pone.0163583.t003g}

  ---------------------- ---------------------- --------------- ---------- ---------- --------- --------------- -----------------------------------------------
  **Male**                                                                                                      
                         **AD-treated cases**                                                                   
                         **VAR+/ADs+**          **VAR-/ADs+**                                                   
                         **SRE+**               **SRE-**        **SRE+**   **SRE-**   **ROR**   **ROR 95%CI**   **p-value**
  All AD-treated cases   56                     9               1574       1621       6.37      3.14--12.90     \< 0.001[\*](#t003fn002){ref-type="table-fn"}
  Bupropion              8                      1               178        185        8.31      1.03--67.16     0.047
  Venlafaxine            5                      1               282        286        5.07      0.59--43.68     0.14
  Sertraline             8                      2               372        378        4.06      0.86--19.27     0.078
  Fluoxetine             10                     3               236        243        3.43      0.93--12.62     0.064
  Trazodone              1                      1               19         19         1         0.01--82.52     1.000
  Mirtazapine            8                      0               49         57         Inf       1.86---Inf      not calculated
  Duloxetine             6                      0               184        190        Inf       1.19---Inf      not calculated
  Amitriptyline          1                      0               80         81         Inf       0.03---Inf      not calculated
  **Female**                                                                                                    
                         **AD-treated cases**                                                                   
                         **VAR+/ADs+**          **VAR-/ADs+**                                                   
                         **SRE+**               **SRE-**        **SRE+**   **SRE-**   **ROR**   **ROR 95%CI**   **p-value**
  All AD-treated cases   174                    21              2884       3037       8.23      5.53--13.76     \< 0.001[\*](#t003fn002){ref-type="table-fn"}
  Sertraline             24                     1               456        479        25.21     3.40--187.13    0.002[\*](#t003fn002){ref-type="table-fn"}
  Fluoxetine             32                     4               364        392        8.62      3.02--24.60     \< 0.001[\*](#t003fn002){ref-type="table-fn"}
  Venlafaxine            28                     4               483        507        7.35      2.56--21.10     \< 0.001[\*](#t003fn002){ref-type="table-fn"}
  Trazodone              6                      1               52         57         6.58      0.77--56.47     0.086
  Amitriptyline          5                      1               86         90         5.23      0.60--45.71     0.135
  Bupropion              15                     5               216        226        3.14      1.12--8.79      0.029
  Duloxetine             23                     0               383        406        Inf       6.03---Inf      not calculated
  Mirtazapine            6                      0               60         66         Inf       1.23---Inf      not calculated
  ---------------------- ---------------------- --------------- ---------- ---------- --------- --------------- -----------------------------------------------

Inf, infinite.

\* significantly different after Bonferroni's correction for multiple comparisons.

In male cases ([Table 3](#pone.0163583.t003){ref-type="table"}-male), when the type of AD was not specified, concomitantly administered VAR significantly increased the risk of SRE (ROR 6.37, ROR95%CI 3.14--12.90). Regarding ADs, concomitantly administered VAR did not significantly increase the risk of SRE in cases treated with any of the antidepressants tested after the correction of the significance level (see the minimal dataset in [S4 Table](#pone.0163583.s004){ref-type="supplementary-material"}).

Similarly, in female cases ([Table 3](#pone.0163583.t003){ref-type="table"}-female), when the type of AD was not specified, concomitantly administered VAR significantly increased the risk of SRE (ROR 8.23, ROR95%CI 5.53--13.76). Regarding ADs, after the correction of the significance level, concomitantly administered VAR significantly increased the risk of SRE in cases treated with sertraline (ROR 25.21, ROR95%CI 3.40--187.13), fluoxetine (ROR 8.62, ROR95%CI 3.02--24.60), and venlafaxine (ROR 7.35, ROR95%CI 2.56--21.10) (see the minimal dataset in [S4 Table](#pone.0163583.s004){ref-type="supplementary-material"}).

The results of the ROR uniformity test (Breslow-Day Test) and iROR calculation (Mantel-Haenszel Test) for each of the 8 ADs are shown in [Table 4](#pone.0163583.t004){ref-type="table"}. Based on [Table 4](#pone.0163583.t004){ref-type="table"}, when the type of AD was not specified, concomitantly administered VAR significantly increased the risk of SRE (iROR 8.02, iROR95%CI 5.47--11.76). Regarding ADs, concomitantly administered VAR significantly increased the SRE risk in cases treated with sertraline (iROR 10.97, iROR95%CI 3.21--37.51), venlafaxine (iROR 6.88, iROR95%CI 2.67--17.74), fluoxetine (iROR 6.34, iROR95%CI 2.80--14.35), and bupropion (iROR 4.02, iROR95%CI 1.60--10.12). Calculations were not possible for amitriptyline, mirtazapine, or duloxetine because complete data were not available.

10.1371/journal.pone.0163583.t004

###### Uniformity test of ROR (Breslow-Day Test) and calculation of integrated ROR (Mantel-Haenszel Test) in AD-treated cases.

![](pone.0163583.t004){#pone.0163583.t004g}

                         Breslow-Day Test                        Mantel-Haenszel Test                                                                                                                                            
  ---------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- -----------------------------------------------
  All AD-treated cases   0.520                                   1.00                                    0.471                                   8.02                                    5.47--11.76                             \< 0.001[\*](#t004fn003){ref-type="table-fn"}
  Sertraline             2.397                                   1.00                                    0.122                                   10.97                                   3.21--37.51                             \< 0.001[\*](#t004fn003){ref-type="table-fn"}
  Venlafaxine            0.093                                   1.00                                    0.761                                   6.88                                    2.67--17.74                             \< 0.001[\*](#t004fn003){ref-type="table-fn"}
  Fluoxetine             1.210                                   1.00                                    0.271                                   6.34                                    2.80--14.35                             \< 0.001[\*](#t004fn003){ref-type="table-fn"}
  Bupropion              0.708                                   1.00                                    0.400                                   4.02                                    1.60--10.12                             0.002[\*](#t004fn003){ref-type="table-fn"}
  Trazodone              1.204                                   1.00                                    0.273                                   3.71                                    0.67--20.61                             0.172
  Amitriptyline          0.189                                   1.00                                    0.664                                   6.29                                    [\#](#t004fn002){ref-type="table-fn"}   not calculated
  Mirtazapine            [\#](#t004fn002){ref-type="table-fn"}   [\#](#t004fn002){ref-type="table-fn"}   [\#](#t004fn002){ref-type="table-fn"}   [\#](#t004fn002){ref-type="table-fn"}   [\#](#t004fn002){ref-type="table-fn"}   not calculated
  Duloxetine             [\#](#t004fn002){ref-type="table-fn"}   [\#](#t004fn002){ref-type="table-fn"}   [\#](#t004fn002){ref-type="table-fn"}   [\#](#t004fn002){ref-type="table-fn"}   [\#](#t004fn002){ref-type="table-fn"}   not calculated

df, degree of freedom.

^\#^ Calculations were not possible because no case was reported.

\* significantly different after Bonferroni's correction for multiple comparisons.

Discussion {#sec011}
==========

Study 1: Concomitant AD-associated risk of SRE in VAR-treated (SCT) cases {#sec012}
-------------------------------------------------------------------------

In male and female cases, none of the antidepressants tested significantly increased the risk of SRE ([Table 1](#pone.0163583.t001){ref-type="table"}). However, when the genders were combined, concomitant duloxetine significantly increased the risk of SRE over that in the control group ([Table 2](#pone.0163583.t002){ref-type="table"}). Furthermore, although a significant difference was not detected, iROR, i.e., the risk of SRE, varied among the antidepressants concomitantly administered to VAR-treated cases. For example, the risk of amitriptyline-induced SRE was the lowest among the antidepressants tested, but was not significant (ROR = 0.59, ROR95%CI 0.23--1.50). In addition, iROR was less than 1.00 in amitriptyline-treated cases only, suggesting that the concomitant use of amitriptyline reduces the risk of SRE more that in the control group. The number of citalopram-treated cases was high in both genders, and ROR was not uniform in the Breslow-Day Test in citalopram-treated cases only. Thus, the risk of SRE differed between the genders ([Table 1](#pone.0163583.t001){ref-type="table"}). However, the absence of a gender difference has been reported in the drug effects of citalopram \[[@pone.0163583.ref021]\], suggesting that this result was incidental.

Since Carol et al. \[[@pone.0163583.ref022]\] reported that the hazard ratio for AD-associated completed suicide was significantly low in amitriptyline-treated cases only, amitriptyline may have SRE risk-reducing effects. Amitriptyline is more frequently used at specialized medical institutions, and the lower risk of SRE in amitriptyline-treated cases may have been due to the management of depressive symptoms and adverse effects at these medical institutions.

Study 2: The risk of SRE associated with the concomitant administration of VAR (SCT) in AD-treated cases {#sec013}
--------------------------------------------------------------------------------------------------------

It was not possible to calculate iROR95%CI for amitriptyline, mirtazapine, or duloxetine. Concomitantly administered VAR may have increased the risk of SRE, regardless of the type of AD, over that in the control group, showing that SCT with VAR is likely to increase the risk of depression-associated suicide. Amitriptyline decreased the risk of SRE in Study 1, but not in Study 2.

Potential of SCT as a latent factor of SRE {#sec014}
------------------------------------------

The iROR of integrated male and female data in Studies 1 and 2 is shown in [Fig 2A](#pone.0163583.g002){ref-type="fig"}. iROR was high in Study 2, indicating that the concomitant VAR-associated risk in AD-treated cases (Study 2) was higher than the concomitant AD-associated risk in VAR-treated cases (Study 1). However, this comparison was not possible because the background of the control group differed between Studies 1 and 2 (ADs-/VAR+ and VAR-/ADs+, respectively). Thus, assuming that the case groups common to both studies, VAR+/ADs+ and ADs+/VAR+, were similar populations, the iROR of these groups were regarded as 1.00 for the baseline in adjustments. The results obtained are shown in [Fig 2B](#pone.0163583.g002){ref-type="fig"}. VAR-/ADs+ and ADs-/VAR+ were compared in [Fig 2B](#pone.0163583.g002){ref-type="fig"}. The bar graph of ADs-/VAR+ was higher than that of VAR-/ADs+, suggesting that SCT with VAR is a latent factor increasing the risk of SRE more than that by ADs used to treated depression.

![(A) Unadjusted iROR and (B) adjusted iROR of varenicline (VAR) and antidepressants (ADs) determined by matching in each study.](pone.0163583.g002){#pone.0163583.g002}

SCT with VAR has been suggested to increase the risk of SRE. However, it currently remains unclear whether VAR itself has a suicide-inducing effect or SCT induces suicide in smokers already at risk of suicide. Factors inducing suicide include 'issues with patients themselves, such as SCT with VAR and mental disorders' and 'the social environment of patients, such as stigma from a patient's family and medical health professionals' \[[@pone.0163583.ref023]\]. An accurate evaluation of the suicide-inducing risk of the latter is difficult because cases cannot be collected from those reported to FAERS. However, as shown in [Fig 2B](#pone.0163583.g002){ref-type="fig"}, the risk of SRE was higher in ADs-/VAR+, in which stigma was not an inducer of SRE, than in VAR-/ADs+, and this did not overestimate the risk of SRE associated with the administration of VAR.

Limitations {#sec015}
-----------

Data from FAERS were analyzed, but only a small number of case reports included gender, the 3 covariates, and adverse events because FAERS adopts the free-description style, and there were many missing data. For example, out of 57,440 VAR-treated cases that were regarded as an analysis set in Study 1, all covariates were reported in 23,008 cases only, and, thus, approximately 60% were not included in the PS estimation. It is possible that an accurate ROR may not have been calculated.

Since case reports in FAERS are cross-sectional, the order of timing of taking drugs and the development of several diseases in a case is currently unclear. Therefore, cases that started smoking cessation during the treatment of depression may have been included among cases that developed depression during SCT, thereby influencing the ROR estimation.

Since the number of covariates is ideally 1/10-1/7 of the number of cases in PS estimations, the number of covariates was insufficient in the present study. When PS is estimated and matched in analyses with a small number of covariates, it is possible that cases with close PS, but a different balance of covariates were matched.

Conclusion {#sec016}
==========

The treatment of depression with ADs during SCT with VAR is more likely to increase the risk of SRE more than that with the treatment of depression with ADs (control group). SCT with VAR has been suggested as a latent factor inducing depression and SRE, and the risk associated with this treatment is stronger than that associated with the treatment of depression with ADs.

When depression develops during SCT, the risk of SRE increases, for which concomitant amitriptyline may decrease the risk of suicide. In contrast, concomitant mirtazapine may increase the risk of SRE because its iROR was the highest.

Supporting Information {#sec017}
======================

###### Changes in the number of cases treated with each drug in steps used for ROR calculations.

(XLSX)

###### 

Click here for additional data file.

###### Balance of covariates by standardized difference (SDD) in VAR-treated and AD-treated cases.

(XLSX)

###### 

Click here for additional data file.

###### The minimal dataset underlying results obtained in Study 1.

Report No. is the report number in CzeekV, NCD stands for the number of concomitant drugs, and SRE represents whether SRE were reported.

(XLSX)

###### 

Click here for additional data file.

###### The minimal dataset underlying results obtained in Study 2.

Report No. is the report number in CzeekV, NCD stands for the number of concomitant drugs, SRE represents whether SRE were reported, and VAR represents whether VAR was used.

(XLSX)

###### 

Click here for additional data file.
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